TABLE 2.

Primary tumor subtype among Cancer COVID‐19 Cohort

Primary tumor subtype	Patients, no. (%)
	Total (n = 166)	Hospital mortality		1‐year mortality
		Dead (n = 34)	Alive (n = 132)	Dead (n = 49)	Alive (n = 117)
Total	166 (100)	34 (20)	132 (80)	49 (30)	117 (70)
Solid tumors	149 (90)	26 (17)	124 (83)	38 (26)	111 (74)
Thyroid and breast	33 (20)	2 (6)	33 (84)	2 (6)	33 (84)
Thyroid	14 (8)	0	14 (100)	0	14 (100)
Breast	19 (11)	2 (11)	17 (89)	2 (11)	17 (89)
Female genital	16 (9)	1 (6)	15 (94)	2 (13)	14 (87)
Cervical	9 (5)	1 (11)	8 (89)	1 (11)	8 (89)
Ovary	4 (2)	0	4 (100)	1 (25)	3 (75)
Endometrial	3 (2)	0	3 (100)	0	3 (100)
Genitourinary	22 (13)	3 (14)	19 (86)	3 (14)	19 (86)
Prostatic	7 (4)	2 (29)	5 (71)	2 (29)	5 (71)
Bladder	7 (4)	0	7 (100)	0	7 (100)
Renal	5 (3)	1 (20)	4 (80)	1 (20)	4 (80)
Penile	2 (1)	0	2 (100)	0	2 (100)
Testicular	1 (1)	0	1 (100)	0	1 (100)
Lung	25 (15)	4 (16)	21 (84)	8 (32)	17 (68)
Digestive system	42 (25)	12 (29)	30 (71)	18 (43)	24 (57)
Colon	18 (11)	3 (17)	15 (83)	7 (39)	11 (61)
Gastric	10 (6)	5 (50)	5 (50)	5 (50)	5 (50)
Liver	6 (4)	1 (17)	5 (83)	2 (33)	4 (67)
Rectal	5 (3)	2 (40)	3 (60)	2 (40)	3 (60)
Pancreas	3 (2)	1 (33)	2 (67)	2 (67)	1 (33)
Other solid	11 (7)	4 (36)	7 (64)	5 (45)	6 (55)
Bone	4 (2)	0	4 (100)	1 (25)	3 (75)
Nasopharyngeal	4 (2)	2 (50)	2 (50)	2 (50)	2 (50)
Brain	2 (1)	1 (50)	1 (50)	1 (50)	1 (50)
Skin	1 (1)	1 (100)	0	1 (100)	0
Hematologic malignancies	17 (10)	8 (47)	9 (53)	11 (65)	6 (35)
Lymphoid malignancy	14 (8)	7 (50)	7 (50)	9 (64)	5 (36)
Multiple myeloma	6 (4)	4 (67)	2 (33)	5 (83)	1 (17)
Non‐Hodgkin lymphoma	4 (2)	1 (25)	3 (75)	2 (50)	2 (50)
Chronic lymphoblastic leukemia	2 (1)	0	2 (100)	0	2 (100)
Acute lymphoblastic leukemia	2 (1)	2 (100)	0	2 (100)	0
Myeloid malignancy	3 (2)	1 (33)	2 (67)	2 (67)	1 (33)
Acute myelogenous leukemia	2 (1)	1 (50)	1 (50)	2 (100)	0
Myelodysplastic syndrome	1 (1)	0	1 (100)	0	1 (100)